The phase 1/2 KEYMAKER-U02 trial evaluating pembrolizumab alone or as a combination therapy in stage IIIB-D melanoma found no adverse event–related deaths.
Health Professionals
Nevus-Associated Acral Melanoma Has Better Survival Outcomes Than De Novo
Nevus-associated acral melanoma (NAAM) demonstrates better recurrence-free survival and overall survival compared with de novo acral melanoma (DNAM), indicating a potentially more favorable prognosis for patients with NAAM, according to study results published in the Journal of the American Academy of Dermatology.
Dabrafenib-Trametinib Combo Shows Activity as Second-Line Adjuvant Therapy in Advanced Melanoma
Second-line adjuvant treatment with dabrafenib and trametinib appeared effective in a small study of patients with BRAF V600-mutated, resected, stage III/IV melanoma, researchers found. In fact, more than 80% of patients were free from relapse and metastasis at 1 year. These results were published in The Oncologist.
BMS-986253 Plus Nivolumab/Ipilimumab Fails to Boost Responses in Advanced Melanoma After Prior Anti–PD-(L)1 Therapy
BMS-986253 plus nivolumab/ipilimumab failed to improve responses or PFS in advanced melanoma after progression on or after a checkpoint inhibitor.